Compare HP Inc (HPQ) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
HP Inc vs Medpace Holdings Inc — how do they compare? HP Inc trades at $30.2 (market cap $29.25B), while Medpace Holdings Inc trades at $612.05 (market cap $16.82B). The key difference: HP Inc is the larger of the two by market cap, and HP Inc pays a 3.7% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold HP Inc for 69 Days and Medpace Holdings Inc for 14 Days on average.
| HPQ | MEDP | |
|---|---|---|
Market Cap | $29.25B | $16.82B |
Volume | 10,025,806 | 223,093 |
Sector | Technology | Health |
52-Week High | $35.48 | $630.19 |
52-Week Low | $18.20 | $393.42 |
Typical Hold Time | 69 Days | 14 Days |
Enterprise Value | $35.42B | $16.44B |
Dividend Yield | 3.7% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HPQ trades at $32.44, up 0.62% with a bullish technical signal. The stock shows strong earnings momentum with three consecutive quarterly beats and maintains solid cash flow generation of $460M in 2025. Valuation appears attractive with P/E of 12.38 and P/S of 0.51, though the company faces headwinds from projected PC market declines in 2027.
HPQ offers value characteristics with reasonable valuation metrics and consistent dividend payments, but faces significant business risks from PC market contraction. Analyst sentiment is mixed with 30.8% buy ratings versus 53.8% holds, reflecting uncertainty about growth prospects amid industry challenges.
Medpace (MEDP) trades at $602.70, down 0.26% with neutral technical signals. The stock shows strong fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and robust profitability (17.67% net margin, 162.15% ROE). Recent CEO stock sales and mixed institutional activity create near-term uncertainty, though analyst consensus remains positive with a $620.44 price target. The company is scheduled to report Q3 2026 results on October 21, 2026.
MEDP presents a compelling growth story with strong financial metrics, though elevated valuations (P/E 35.41) and insider selling warrant caution. Upside potential exists if Q3 earnings meet expectations, while failure to maintain growth momentum could pressure the stock. The current price near pivot point ($599) suggests balanced risk-reward ahead of earnings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About HP Inc
HP Incorporated is a leading provider of computers, printers, and printer supplies. The company's mains segments are personal systems and printing. Its personal systems segment contains notebooks, desktops, and workstations. Its printing segment contains supplies, consumer hardware, and commercial hardware. In 2015, Hewlett-Packard was separated into HP Incorporated and Hewlett Packard Enterprise and the Palo Alto, California-based HP Incorporated sells on a global scale.
Read more on HPQ →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
